MK0557

DRUG5 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

ObesityParanoid SchizophreniaSchizophrenia

Phase 2

MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)

CompletedNCT00482430

Merck Sharp & Dohme LLCParanoid Schizophrenia, Schizophrenia

Start: 2007-09-30End: 2008-10-31Updated: 2015-08-21

Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

CompletedNCT00533481

Merck Sharp & Dohme LLCObesity

Start: 2004-02-29End: 2004-12-31Updated: 2016-09-16

A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)

CompletedNCT00533598

Merck Sharp & Dohme LLCObesity

Start: 2002-09-30End: 2003-06-30Updated: 2016-09-07

Phase 3

A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)

CompletedNCT00092872

Merck Sharp & Dohme LLCObesity

Start: 2003-11-30End: 2005-02-28Updated: 2015-01-30

A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)

CompletedNCT00092859

Merck Sharp & Dohme LLCObesity

Start: 2003-08-31End: 2005-06-30Updated: 2017-01-02